H22 Syngeneic Model Overview

The H22 syngeneic model is a murine hepatocellular carcinoma (HCC) system originally derived from a spontaneous liver tumor in a male mouse of the ICR strain. When transplanted into immunocompetent hosts, particularly BALB/c mice, H22 cells form aggressive, vascularized tumors that exhibit hallmark features of hepatocellular carcinoma, including high mitotic activity, vascular invasion, and local metastasis. The model has been extensively utilized for preclinical evaluation of chemotherapy, immunotherapy, and hepatoprotective agents.

The H22 model’s rapid growth kinetics and predictable tumor establishment make it ideal for short-term efficacy studies, while its hepatic origin provides translational relevance for drug development in liver cancer. H22 can be implanted either subcutaneously for convenient measurement of tumor volume or orthotopically into the liver to recapitulate the microenvironmental complexity of hepatocellular carcinoma, including hypoxia, fibrosis, and immune suppression.

Request a Custom Quote for H22 Syngeneic Model

Biological and Molecular Characteristics

The H22 cell line exhibits polygonal epithelial morphology consistent with hepatocyte origin and forms dense, solid tumors upon implantation. The cells produce high levels of liver-specific enzymes such as alanine transaminase (ALT) and aspartate transaminase (AST) and express characteristic markers of hepatocellular carcinoma including alpha-fetoprotein (AFP), albumin, and cytokeratins. Tumors are highly vascularized and demonstrate metabolic profiles typical of fast-growing liver carcinomas, including elevated glycolytic activity and lipid accumulation.

Immunologically, H22 tumors display moderate immunogenicity and induce infiltration of macrophages, myeloid cells, and regulatory T lymphocytes, resulting in partial immune evasion. The tumor microenvironment is rich in inflammatory cytokines such as IL-6 and TGF-beta, which promote fibrosis and tumor progression. This immunosuppressive milieu closely parallels human hepatocellular carcinoma, providing a clinically relevant context for evaluating immune-based and anti-fibrotic interventions.

Parameter	Description
Host strain	BALB/c (female, 6–8 weeks)
Tumor origin	Spontaneous hepatocellular carcinoma (mouse)
Histological type	Poorly differentiated carcinoma
Inoculation route	Subcutaneous or orthotopic (liver)
Tumor take rate	>95%
Doubling time	Approximately 3–4 days in vivo
Metastatic potential	Moderate; local invasion and hepatic spread
Immunophenotype	Mixed lymphocytic and macrophage infiltration
Common applications	Chemotherapy, immunotherapy, hepatoprotective compound testing

In Vivo Model Development and Tumorigenicity

The H22 model can be established through subcutaneous or orthotopic implantation of tumor cells into immunocompetent BALB/c mice. Subcutaneous inoculation produces rapidly growing, measurable tumors within 4–6 days, enabling high-throughput drug efficacy testing. Orthotopic implantation into the liver generates tumors that reproduce the complex vascularization, hepatic microenvironment, and immune interactions characteristic of human HCC.

H22 tumors are highly aggressive and exhibit reproducible kinetics, with consistent tumor take rates across experimental cohorts. Due to their rapid progression and rich vasculature, these tumors are particularly suitable for studying angiogenesis inhibitors, hepatoprotective agents, and immune-modulating drugs. The model’s capacity for both subcutaneous and hepatic growth provides flexibility for evaluating systemic and localized treatment effects in preclinical liver cancer research.

Request a Custom Quote for H22 Syngeneic Model

Histopathology and Immunohistochemical Profile

Histopathological analysis of H22 tumors reveals dense sheets of polygonal cells with large nuclei, prominent nucleoli, and minimal cytoplasmic differentiation. The tumor parenchyma is interspersed with sinusoidal vascular channels and regions of necrosis surrounded by viable hepatoma cells. Fibrotic stroma and infiltrating immune cells are often present, contributing to the tumor’s structural complexity.

Immunohistochemical staining demonstrates strong expression of hepatocellular markers such as alpha-fetoprotein and albumin, confirming hepatic differentiation. Ki-67 staining indicates high proliferative activity, while CD31 and VEGF staining reveal extensive angiogenesis. CD3 and CD8 staining highlight scattered T-cell infiltration, and F4/80 identifies macrophage accumulation at the tumor margins. PD-L1 expression is moderate but inducible following cytokine exposure, consistent with an immune-evasive phenotype. These histological features make the H22 model well-suited for translational studies of hepatocellular carcinoma biology and therapy.

Preclinical Applications and Drug Response

The H22 syngeneic model has been used for decades as a benchmark in hepatocellular carcinoma research and drug screening. It supports evaluation of chemotherapy agents such as doxorubicin, cisplatin, and 5-fluorouracil, as well as targeted and immune-based therapies. Owing to its rapid growth and defined immunological profile, H22 serves as a reliable system for assessing combination therapies that integrate immune checkpoint inhibitors, cytokine agonists, or angiogenesis blockers.

The model also provides a reproducible platform for testing hepatoprotective or anti-fibrotic agents in the context of tumor-associated liver injury. Its responsiveness to immune modulation and stromal targeting allows researchers to investigate mechanisms of immune suppression, hepatocyte regeneration, and therapy-induced liver toxicity. Overall, the H22 model remains a versatile and translationally relevant system for the preclinical development of anti-cancer and liver-protective therapeutics.

Request This Model

To request the H22 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.

Request a Custom Quote for H22 Syngeneic Model